Radiographic Phenotypes Affect the Risk of Inhaled Corticosteroid-Associated Pneumonia in Patients with COPD

References

• (GOLD) GIfCOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease: 2021 report. Available from: www.goldcopd.org. Accessed September 30, 2021.
   Google Scholar
• 2019 global strategy for prevention, diagnosis and management of COPD; 2019. Available from: https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019-v1.7-FINAL-14Nov2018-WMS.pdf. Accessed September 13, 2022.
   Google Scholar
• 2022 global strategy for diagnosis, management and prevention of chronic obstructive pulmonary disease. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed September 13, 2022.
   Google Scholar
• Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356(8):775–789. doi:10.1056/NEJMoa063070
   PubMed Web of Science ®Google Scholar
• Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl J Med. 2016;374(23):2222–2234. doi:10.1056/NEJMoa1516385
   PubMed Web of Science ®Google Scholar
• Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):Cd010115. doi:10.1002/14651858.CD010115.pub2
   PubMed Web of Science ®Google Scholar
• Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378(18):1671–1680. doi:10.1056/NEJMoa1713901
   PubMed Web of Science ®Google Scholar
• Edsbäcker S, Wollmer P, Selroos O, Borgström L, Olsson B, Ingelf J. Do airway clearance mechanisms influence the local and systemic effects of inhaled corticosteroids? Pulm Pharmacol Ther. 2008;21(2):247–258. doi:10.1016/j.pupt.2007.08.005
   PubMed Web of Science ®Google Scholar
• Rossios C, To Y, To M, et al. Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. Eur J Pharmacol. 2011;670(1):244–251. doi:10.1016/j.ejphar.2011.08.022
   PubMed Web of Science ®Google Scholar
• Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids. J Allergy Clin Immunol. 1998;101(4 Pt 2):S434–9. doi:10.1016/S0091-6749(98)70155-1
   PubMed Web of Science ®Google Scholar
• Johnson M. Pharmacodynamics and pharmacokinetics of inhaled glucocorticoids. J Allergy Clin Immunol. 1996;97(1 Pt 2):169–176. doi:10.1016/S0091-6749(96)80217-X
   PubMed Web of Science ®Google Scholar
• Huang YJ, Sethi S, Murphy T, Nariya S, Boushey HA, Lynch SV. Airway microbiome dynamics in exacerbations of chronic obstructive pulmonary disease. J Clin Microbiol. 2014;52(8):2813–2823. doi:10.1128/jcm.00035-14
   PubMed Web of Science ®Google Scholar
• Pragman AA, Kim HB, Reilly CS, Wendt C, Isaacson RE. The lung microbiome in moderate and severe chronic obstructive pulmonary disease. PLoS One. 2012;7(10):e47305. doi:10.1371/journal.pone.0047305
   PubMed Web of Science ®Google Scholar
• Donnelly LE, Barnes PJ. Defective phagocytosis in airways disease. Chest. 2012;141(4):1055–1062. doi:10.1378/chest.11-2348
   PubMed Web of Science ®Google Scholar
• Knowles MR, Boucher RC. Mucus clearance as a primary innate defense mechanism for mammalian airways. J Clin Invest. 2002;109(5):571–577. doi:10.1172/JCI0215217
   PubMed Web of Science ®Google Scholar
• Restrepo MI, Sibila O, Anzueto A. Pneumonia in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis. 2018;81(3):187–197. doi:10.4046/trd.2018.0030
   PubMed Web of Science ®Google Scholar
• Bafadhel M, Umar I, Gupta S, et al. The role of CT scanning in multidimensional phenotyping of COPD. Chest. 2011;140(3):634–642. doi:10.1378/chest.10-3007
   PubMed Web of Science ®Google Scholar
• Lynch DA, Austin JH, Hogg JC, et al. CT-definable subtypes of chronic obstructive pulmonary disease: a statement of the Fleischner society. Radiology. 2015;277(1):192–205. doi:10.1148/radiol.2015141579
   PubMed Web of Science ®Google Scholar
• Mair G, Maclay J, Miller JJ, et al. Airway dimensions in COPD: relationships with clinical variables. Respir Med. 2010;104(11):1683–1690. doi:10.1016/j.rmed.2010.04.021
   PubMed Web of Science ®Google Scholar
• Singh D. Small airway disease in patients with chronic obstructive pulmonary disease. Tuberc Respir Dis. 2017;80(4):317–324. doi:10.4046/trd.2017.0080
   PubMed Web of Science ®Google Scholar
• Martinez-Garcia MA, Miravitlles M. Bronchiectasis in COPD patients: more than a comorbidity? Int J Chron Obstruct Pulmon Dis. 2017;12:1401–1411. doi:10.2147/copd.S132961
   PubMed Web of Science ®Google Scholar
• DiSantostefano RL, Li H, Hinds D, Galkin DV, Rubin DB. Risk of pneumonia with inhaled corticosteroid/long-acting β2 agonist therapy in chronic obstructive pulmonary disease: a cluster analysis. Int J Chron Obstruct Pulmon Dis. 2014;9:457–468. doi:10.2147/copd.S60498
   PubMed Web of Science ®Google Scholar
• Rennard SI. COPD: overview of definitions, epidemiology, and factors influencing its development. Chest. 1998;113(4Suppl):235s–241s. doi:10.1378/chest.113.4_supplement.235s
   PubMed Web of Science ®Google Scholar
• Luijendijk SC, van der Grinten CP. The ratio of the alveolar ventilations of SF6 and He in patients with lung emphysema and in healthy subjects. Respir Physiol Neurobiol. 2002;130(1):69–77. doi:10.1016/S0034-5687(01)00326-7
   PubMed Web of Science ®Google Scholar
• Sturm R. Theoretical diagnosis of emphysema by aerosol bolus inhalation. Ann Transl Med. 2017;5(7):154. doi:10.21037/atm.2017.03.28
   PubMed Web of Science ®Google Scholar
• Verbanck S, Schuermans D, Vincken W, Paiva M. Saline aerosol bolus dispersion. I. The effect of acinar airway alteration. J Appl Psysiol. 2001;90(5):1754–1762. doi:10.1152/jappl.2001.90.5.1754
   PubMed Web of Science ®Google Scholar
• Kohlhäufl M, Brand P, Rock C, et al. Noninvasive diagnosis of emphysema. Aerosol morphometry and aerosol bolus dispersion in comparison to HRCT. Am J Respir Crit Care Med. 1999;160(3):913–918. doi:10.1164/ajrccm.160.3.9811051
   PubMed Web of Science ®Google Scholar
• Saari SM, Vidgren MT, Koskinen MO, Turjanmaa VM, Waldrep JC, Nieminen MM. Regional lung deposition and clearance of 99mTc-labeled beclomethasone-DLPC liposomes in mild and severe asthma. Chest. 1998;113(6):1573–1579. doi:10.1378/chest.113.6.1573
   PubMed Web of Science ®Google Scholar
• Chung KF, Jeyasingh K, Snashall PD. Influence of airway calibre on the intrapulmonary dose and distribution of inhaled aerosol in normal and asthmatic subjects. Eur Respir J. 1988;1(10):890–895.
   PubMed Web of Science ®Google Scholar
• von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457. doi:10.1016/S0140-6736(07)61602-X
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Papi A, Anzueto A, et al. Budesonide/formoterol MDI with co-suspension delivery technology in COPD: the TELOS study. Eur Respir J. 2018;52(3):1801334. doi:10.1183/13993003.01334-2018
   PubMed Web of Science ®Google Scholar
• Pasteur MC, Bilton D, Hill AT. British thoracic society guideline for non-CF bronchiectasis. Thorax. 2010;65(Suppl 1):i1–58. doi:10.1136/thx.2010.136119
   PubMed Web of Science ®Google Scholar
• Hansell DM, Bankier AA, MacMahon H, McLoud TC, Müller NL, Remy J. Fleischner Society: glossary of terms for thoracic imaging. Radiology. 2008;246(3):697–722. doi:10.1148/radiol.2462070712
   PubMed Web of Science ®Google Scholar
• Jairam PM, van der Graaf Y, Lammers JW, Mali WP, de Jong PA. Incidental findings on chest CT imaging are associated with increased COPD exacerbations and mortality. Thorax. 2015;70(8):725–731. doi:10.1136/thoraxjnl-2014-206160
   PubMed Web of Science ®Google Scholar
• Goddard PR, Nicholson EM, Laszlo G, Watt I. Computed tomography in pulmonary emphysema. Clin Radiol. 1982;33(4):379–387. doi:10.1016/S0140-6736(07)61602-X
   PubMed Web of Science ®Google Scholar
• Dou S, Zheng C, Cui L, et al. High prevalence of bronchiectasis in emphysema-predominant COPD patients. Int J Chron Obstruct Pulmon Dis. 2018;13:2041–2047. doi:10.2147/copd.S163243
   PubMed Web of Science ®Google Scholar
• Sturm R, Pawłak E, Hofmann W. Monte-Carlo-Modell der Aerosolbolusdispersion in der menschlichen Lunge--Teil 2: modellvorhersagen für die kranke Lunge [Monte-Carlo-Model for the aerosol bolus dispersion in the human lung--part 2: model predictions for the diseased lung]. Z Med Phys. 2007;17(2):136–143. doi:10.1016/j.zemedi.2006.10.010
   PubMed Web of Science ®Google Scholar
• Hofmann W, Pawlak E, Sturm R. Semi-empirical stochastic model of aerosol bolus dispersion in the human lung. Inhal Toxicol. 2008;20(12):1059–1073. doi:10.1080/08958370802115081
   PubMed Web of Science ®Google Scholar
• Luisetti M, Seersholm N. Alpha1-antitrypsin deficiency. 1: epidemiology of alpha1-antitrypsin deficiency. Thorax. 2004;59(2):164–169. doi:10.1136/thorax.2003.006494
   PubMed Web of Science ®Google Scholar
• Sturm R. Theoretical models for the simulation of particle deposition and tracheobronchial clearance in lungs of patients with chronic bronchitis. Ann Transl Med. 2013;1(1):3. doi:10.3978/j.issn.2305-5839.2012.11.02
   PubMedGoogle Scholar
• Sturm R. A computer model for the simulation of nanoparticle deposition in the alveolar structures of the human lungs. Ann Transl Med. 2015;3(19):281. doi:10.3978/j.issn.2305-5839.2015.11.01
   PubMed Web of Science ®Google Scholar
• Thorsson L, Kenyon CJ, Newman S, Borgström L. Lung deposition of budesonide in asthmatics: a comparison of different formulations. Int J Pharmaceut. 1998;168:119–127.
   Web of Science ®Google Scholar
• Brown JS, Zeman KL, Bennett WD. Ultrafine particle deposition and clearance in the healthy and obstructed lung. Am J Respir Crit Care Med. 2002;166(9):1240–1247. doi:10.1164/rccm.200205-399OC
   PubMed Web of Science ®Google Scholar
• Camner P, Mossberg B, Philipson K. Tracheobronchial clearance and chronic obstructive lung disease. Scand J Respir Dis. 1973;54(5):272–281.
   PubMedGoogle Scholar
• Vastag E, Matthys H, Zsamboki G, Köhler D, Daikeler G. Mucociliary clearance in smokers. Eur J Respir Dis. 1986;68(2):107–113.
   PubMedGoogle Scholar
• Gatheral T, Kumar N, Sansom B, et al. COPD-related bronchiectasis; independent impact on disease course and outcomes. Copd. 2014;11(6):605–614. doi:10.3109/15412555.2014.922174
   PubMedGoogle Scholar
• Han MK, Agusti A, Calverley PM, et al. Chronic obstructive pulmonary disease phenotypes: the future of COPD. Am J Respir Crit Care Med. 2010;182(5):598–604. doi:10.1164/rccm.200912-1843CC
   PubMed Web of Science ®Google Scholar
• Traversi L, Miravitlles M, Martinez-Garcia MA, et al. ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. ERJ Open Res. 2021;7(4):00399–2021. doi:10.1183/23120541.00399-2021
   PubMedGoogle Scholar
• Crystal RG. Airway basal cells. The ”smoking gun” of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2014;190(12):1355–1362. doi:10.1164/rccm.201408-1492PP
   PubMed Web of Science ®Google Scholar
• Shaykhiev R, Crystal RG. Early events in the pathogenesis of chronic obstructive pulmonary disease. Smoking-induced reprogramming of airway epithelial basal progenitor cells. Ann Am Thorac Soc. 2014;11 Suppl 5(Suppl5):S252–8. doi:10.1513/AnnalsATS.201402-049AW
   PubMedGoogle Scholar
• Sakai F, Tominaga J, Kaga A, et al. Imaging diagnosis of interstitial pneumonia with emphysema (combined pulmonary fibrosis and emphysema). Pulm Med. 2012;2012:816541. doi:10.1155/2012/816541
   PubMedGoogle Scholar
• Alsumrain M, De Giacomi F, Nasim F, et al. Combined pulmonary fibrosis and emphysema as a clinicoradiologic entity: characterization of presenting lung fibrosis and implications for survival. Respir Med. 2019;146:106–112. doi:10.1016/j.rmed.2018.12.003
   PubMed Web of Science ®Google Scholar
• Kitaguchi Y, Fujimoto K, Hanaoka M, Honda T, Hotta J, Hirayama J. Pulmonary function impairment in patients with combined pulmonary fibrosis and emphysema with and without airflow obstruction. Int J Chron Obstruct Pulmon Dis. 2014;9:805–811. doi:10.2147/copd.S65621
   PubMed Web of Science ®Google Scholar
• London U. Inhaled corticosteroids (ICS) containing medicinal products indicated in the treatment of chronic obstructive pulmonary disease (COPD). Eur Med Agency. 2016;2016:5.
   Google Scholar